Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Completed 4Withdrawn 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other hematologic neoplasm 5Myeloid 1

Conditions

Myeloproliferative Disorders 7Hematologic Neoplasms 5Primary Myelofibrosis 4Thrombocythemia, Essential 1Solid Tumor 1Polycythemia Vera 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Blast Crisis 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × fedratinib × Clear all
NCT01420770 2025-03-05

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Bristol-Myers Squibb

Phase 2 Completed
30 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01420783 2025-03-05

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Bristol-Myers Squibb

Phase 2 Completed
81 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT01437787 2025-03-05

JAKARTA

Bristol-Myers Squibb

Phase 3 Completed
289 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

NCT01523171 2025-03-05

JAKARTA2

Bristol-Myers Squibb

Phase 2 Completed
97 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡